エンジニアリングされた免疫アゴニスト非コーディングRNA (incRNA) が,がん免疫療法のための二重TLR経路を活性化します

James Forster¹, Adam Fish¹, Mehak Malhotra¹

¹Department of Chemical Engineering, University of Massachusetts, Amherst, MA, 01003, USA.

Advanced healthcare materials

|September 4, 2025

まとめ

この研究は,免疫系を抑制する代わりに免疫系を活性化する新しい治療法である免疫原発性非コーディングRNA (incRNA) を導入した. このアプローチはRNAを活用しています.

科学分野:

免疫学
RNAセラピー
腫瘍学

背景:

従来のmRNA療法では,免疫原性を最小限に抑えることに重点を置いています.
免疫性は治療的に有利である.
広範なmRNA改変は必ずしも必要ではない.

研究の目的:

免疫アゴニスト非コーディングRNA (incRNA) を新しい治療クラスとして導入する.
生まれながらの免疫活性化を利用する
普遍的なmRNA改変の必要性に挑戦する

主な方法:

改変された核酸を含まない非コーディングDNAテンプレートからのインビトロ転写.
脂質ナノ粒子 (LNP) の封じ込めとインクRNAの配送
免疫細胞の再プログラム (マクロファージの再極化, dendritic 細胞の成熟) のin vitro評価
抗PD-1との併用療法を含む,メラノーママウスモデルにおけるin vivo試験

主要な成果:

incRNAは, in vitroで強く誘発された免疫的再プログラムである.
強力な二重パターン認識:20倍以上のTLR3/インターフェロン (dsRNA) と6倍以上のTLR7/TNF-α (ssRNA) 信号.
生体内での incRNA配分は,先天性および適応性免疫細胞の増殖を促した.
メラノーマのモデルで顕著な腫瘍収縮が観察された.
抗PD-1チェックポイント阻害と併用すると免疫力を高めます

結論:

RNA療法の有効性は文脈に依存しています.
固有のRNA免疫性を活用することで,治療効果を高めることができます.
incRNAはがん治療における生まれつきの免疫を活用する有望な戦略です

キーワード:

TLRアゴニストガンに対する免疫療法免疫工学生まれつきの免疫非コーディングRNA

さらに関連する動画

09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

790

09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

関連する概念動画

01:27

Tumor Immunotherapy

658

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

658

02:39

lncRNA - Long Non-coding RNAs

8.9K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

8.9K

02:15

Experimental RNAi

6.2K

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

6.2K

02:53

Adaptive Mechanisms in Cancer Cells

5.9K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

5.9K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

03:03

mTOR Signaling and Cancer Progression

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...